<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>491</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>493</td>
<td>CCR 20th Anniversary Commentary</td>
<td>Susan J. Knox and Ronald Levy</td>
</tr>
<tr>
<td>495</td>
<td>CCR Translations</td>
<td>Gabriel S. Kripfeld and Christine H. Chung</td>
</tr>
<tr>
<td>498</td>
<td>Molecular Pathways</td>
<td>Michelle Cicchini, Vassiliki Karantza, and Bing Xia</td>
</tr>
<tr>
<td>505</td>
<td>Molecular Pathways</td>
<td>Verline Justilien and Alan P. Fields</td>
</tr>
<tr>
<td>526</td>
<td>Review</td>
<td>Netanya I. Pollock and Jennifer R. Grandis</td>
</tr>
<tr>
<td>544</td>
<td>Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck</td>
<td>Han Sang Kim, Hyoeng Ju Kwon, Inkyung Jung, Mi Ran Yun, Hyung Ju Ahn, Byung Woong Kang, Jongsunyu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Wook Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Ji Hee Sohn, Bom Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soomymung Paik, and Byoung Chul Cho</td>
</tr>
<tr>
<td>561</td>
<td>PERSONALIZED MEDICINE AND IMAGING</td>
<td>The High-Dose Aldesleukin &quot;Select&quot; Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma</td>
</tr>
</tbody>
</table>
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Spertus, Dominique Agher-Tahb, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluís Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidingmann, Joaquín Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, and Jose Baselga

Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer


A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma


Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models

Povilas Sladkevicius and Lil Valentin

Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer

Justin Bottsford-Miller, Hyun-Jin Choi, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Monika Haemmerle, Alpa M. Nick, Sunila Pradeep, Behrouz Zand, Rebecca A. Previs, Chad V. Pecot, Erin King Crane, Wei Hu, Susan J. Lutgendorf, Vahid Afshar-Kharghan, and Anil K. Sood

Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy

Jessica Ann Chacon, Amod A. Sarnaik, Jie Qing Chen, Caitlin Ceesay, Charuta Kale, John Robinson, Jeffrey Weber, Patrick Hwu, Shari Pilon-Thomas, and Laszlo Radvanyi

Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection


Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas


Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

Tatsuya Yoshida, Genichiro Ishii, Koichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Shinsuke Iida, Akio Niimi, Kanji Nagai, Yuichiro Ohe, and Atsushi Ochiai
### Table of Contents

**Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer**

Francisco J. Candido-dos-Reis, Honglin Song, Ellen L. Goode, Julie M. Cunningham, Brooke L. Fridley, Melissa C. Larson, Kathryn Alsop, Ed Dicks, Patricia Harrington, Susan J. Ramus, Anna de Fazio, Gillian Mitchell, Sian Fereday, Kelly L. Bolton, Charlie Gourley, Caroline Michie, Beth Karlan, Jenny Lester, Christine Walsh, Ilana Cass, Håkan Olsson, Martin Gore, Javier J. Benitez, Maria J. García, Irene Andulius, Anna Marie Mulligan, Gord Glendon, Ignacio Blanco, Comi Lazarro, Alice S. Whitemore, Valerie McGuire, Weiva Sieh, Marco Montagna, Elisa Alducci, Siegal Sadetzki, Angela Chetrit, Ava Kwong, Susanne K. Kjaer, Allan Jensen, Estrid Hugdall, Susan Neuhausen, Robert Nussbaum, Mary Daly, Mark H. Greene, Phuong L. Mai, Jennifer T. Loud, Kirsten Moysich, Amanda E. Toland, Diether Lambrechts, Steve Ellis, Debra Frost, James D. Brenton, Marc Tischkowitz, Douglas F. Easton, Antonis Antoniou, for EMBRACE, Georgia Chenevix-Trench, for kConFab Investigators

### LETTERS TO THE EDITOR

**DNA Repair Mutations and Outcomes in Ovarian Cancer—Letter**

Robert A. Soslow

**DNA Repair Mutations and Outcomes in Ovarian Cancer—Response**

Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, and Rochelle L. Garcia

### CORRECTIONS

**Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer**

**Correction: HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer**

**Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors**

---

### ABOUT THE COVER

The cover shows NFκB translocation in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Immunocytochemistry staining shows NFκB (p65) translocation (red is nucleus; green is NFκB; and yellow is overlay [translocation]) in the nucleus of tumor-infiltrating lymphocytes expanded with IL-2 and an anti-4-1BB antibody. For details, see the article by Chacon and colleagues on page 611 of this issue.